US 9868954
Reduction of TGFβ signaling in myeloid cells in the treatment of cancer
granted A61KA61K2239/49A61K31/4025
Quick answer
US patent 9868954 (Reduction of TGFβ signaling in myeloid cells in the treatment of cancer) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Jan 11 2038 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- The United States of America, as represented by the Secretary, Department of Health and Human Services
- Grant date
- Tue Jan 16 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jan 11 2038 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 15
- CPC classes
- A61K, A61K2239/49, A61K31/4025, A61K31/5377, A61K31/7088